Endologix Appoints John Onopchenko as Chief Operating Officer
October 19 2017 - 8:00AM
Business Wire
Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of
innovative treatments for aortic disorders, announced today that it
has appointed John Onopchenko as the Company’s Chief Operating
Officer, effective October 30, 2017. Mr. Onopchenko will be
responsible for managing Endologix’s manufacturing, supply chain,
and quality organizations.
Mr. Onopchenko brings to Endologix almost thirty years of
executive leadership experience in medical devices. Most recently,
Mr. Onopchenko was Executive Vice President for Acutus Medical,
where he was responsible for program management/product
development, quality, marketing, and sales. Prior to that, he
served on the Board of Directors of Volcano Corporation (“Volcano”)
and later became the company’s Executive Vice President / Chief
Operating Officer. While at Volcano, he was responsible for its
peripheral business unit, regulatory affairs, quality assurance,
program management/product development, clinical affairs, business
development, and the Axsun business unit. Following Volcano’s
acquisition by Philips, John was retained as Senior Vice President
and Head of Therapy Strategy. Before joining Volcano, Mr.
Onopchenko spent 10 years at Johnson & Johnson, where he led
medical device investments with Johnson & Johnson Development
Corporation and was responsible for worldwide operations for
Advanced Sterilization Products.
John McDermott, Chief Executive Officer for Endologix,
said, “We are very excited to welcome John to Endologix’s executive
team. His impressive and versatile leadership expertise will be
invaluable in helping us revolutionize aortic care for life and
build on our position as an innovative leader in the endovascular
aortic market.”
John Onopchenko said, “I am thrilled to join Endologix in this
role. The Company’s dedication to aortic care, coupled with its
breadth of products, uniquely positions Endologix to create great
value for physicians and patients. I look forward to being a part
of the leadership team.”
Mr. Onopchenko earned his MBA from the University of Chicago and
a Bachelor of Science from Ursinus College in Collegeville,
Pennsylvania.
About Endologix
Endologix, Inc. develops and manufactures minimally
invasive treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge
and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading
cause of death in the U.S. For more information,
visit www.endologix.com.
Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “could,” “may,” “will,”
“believe,” “estimate,” “forecast,” “goal,” “project,” "continue,"
"outlook," “guidance,” "future,” other words of similar meaning and
the use of future dates. Forward-looking statements used in this
press release include, but are not limited to, statements regarding
the anticipated commencement (and commensurate benefits) of Mr.
Onopchenko’s employment with Endologix, the accuracy of which are
necessarily subject to risks and uncertainties that may cause
Endologix’s actual results to differ materially and adversely from
the statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ materially
and adversely from anticipated results include Endologix’s ability
to continue integrating the businesses and operations of, and to
realize the expected benefits of its merger with, TriVascular,
continued market acceptance, hiring, integration and retention of
the Endologix’s executive management team, endorsement and use of
Endologix's products (including market acceptance and adoption of
the Nellix EVAS System with its refined IFU), risks associated with
the manufacturing of Endologix’s products, the success of clinical
trials relating to Endologix’s products (including the clinical
results of the EVAS2 study), product research and development
efforts, uncertainty in the process of obtaining and maintaining
U.S. FDA and other regulatory approvals for Endologix's products,
risks associated with international operations, including currency
exchange rate fluctuations, Endologix’s ability to protect its
intellectual property rights and proprietary technologies, and
other economic, business, competitive and regulatory factors. Undue
reliance should not be placed upon the forward-looking statements
contained in this press release, which speak only as of the date of
this press release. Endologix undertakes no obligation to update
any forward-looking statements contained in this press release to
reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events. Please refer to Endologix's filings with the Securities and
Exchange Commission including its Annual Report on Form 10-K for
the year ended December 31, 2016 and subsequent Quarterly
Reports on Form 10-Q, for more detailed information regarding these
risks and uncertainties and other factors that may cause actual
results to differ materially from those expressed or implied.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171019005240/en/
INVESTORS:Endologix, Inc.Vaseem Mahboob, CFO, 949-595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024